Regulators Reassure On AZ Vaccine Safety After Rare Side Effect Deemed Plausible
Vaccine Faces Global Confidence Test
The EMA and MHRA issue parallel safety updates on the vaccine, with the UK offering an alternative of the Pfizer/BioNTech or Moderna vaccines to the under 30s.
You may also be interested in...
The French authorities believe that the “heterologous prime-boost” approach is justified in the case of people aged under 55 years who are due to receive their second dose of the AZ COVID-19 vaccine.
Coronavirus Notebook: EMA Probes Janssen Vaccine Blood Clot Reports, UK Advises 12-Week Dosing Gap For Moderna
The AZ vaccine is now under EU scrutiny over capillary leak syndrome, while Valneva has reported positive results with its product. The global COVAX initiative has delivered more than 38 million doses of vaccines to over a hundred countries.
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.